Brazilian antibody will be used to create new cancer drug

(Fundação de Amparo Pesquisa do Estado de São Paulo) A Brazilian company has signed a licensing agreement with an American laboratory, under which the US-based company's technology will be used to produce a monoclonal antibody (mAb), developed in Brazil, that can be deployed for the purposes of cancer treatment.